<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811954</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5257</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <nct_id>NCT00811954</nct_id>
  </id_info>
  <brief_title>Comparative Study of Three NNRTI-Sparing HAART Regimens</brief_title>
  <official_title>The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected
      patients who have never received anti-HIV therapy be treated with a triple drug regimen. The
      most commonly prescribed and successful regimen contains the medication efavirenz (EFV).
      However, this regimen may not be an option for everyone, hence alternative regimens are
      needed.

      This study was designed to look at how well different combinations of anti-HIV drugs work to
      decrease the amount of HIV in the blood (viral load) of and allow immune system recovery in
      people who have never received anti-HIV therapy. This study also examined drug tolerability
      and safety for the various drug combinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Of the five anti-HIV drug classes, four were recommended as first-line regimens for patients
      who have never received anti-HIV treatment before (treatment naive): nucleoside reverse
      transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs),
      Integrase Inhibitors (INIs) and protease inhibitors (PIs). The U.S. Department of Health and
      Human Services (HHS) guidelines recommend that treatment-naive HIV infected patients be
      treated with a triple drug regimen that includes 2 NRTIs + 1 NNRTI, 2 NRTIs + INI, or 2 NRTIs
      + 1 PI as their initial treatment regimen.

      According to data, an efavirenz (EFV)-containing regimen (2 NRTIs + 1 NNRTI, with EFVas the
      NNRTI) requires fewer pills for the patient, has mild and few side effects, and is more
      effective in reducing viral load than other regimens, making it the preferred choice for most
      patients. However, for some patients, an EFV-containing regimen is not feasible due to side
      effects, acquired NNRTI-resistant HIV virus, or other undesirable effects. For these
      patients, it is necessary to find alternative regimens with comparable safety and efficacy.
      This study examined how well different combinations of anti-HIV drugs work, including safety
      and drug tolerability for various combinations.

      This was a phase III, prospective, randomized study. Participants was randomly assigned to
      one of three different groups (treatment arms)—A, B, or C —each representing a different drug
      combination regimen, none of which contained an NNRTI.

      Arm A: Atazanavir (ATV) + Ritonavir (RTV) + Emtricitabine/tenofovir disoproxil fumarate
      (FTC/TDF)

      Arm B: Raltegravir (RAL) + FTC/TDF

      Arm C: Darunavir (DRV) + RTV + FTC/TDF

      The duration of this study was between 96 and 192 weeks, depending on when the participant
      enrolled. There were a total of 1,809 participants, approximately 600 per treatment arm.
      Screening and pre-entry evaluations must occur prior to the participant starting any study
      medication, treatments, or interventions. Participants were randomly assigned to their
      treatment groups at the entry visit and must begin treatment within 72 hours of
      randomization. Participants was told which group they were in and what medications they were
      administered. The study drugs were distributed at entry. All drugs were provided by the study
      with the exception of RTV, which would have to be obtained through the participant's primary
      care physician (Group A or C). If a participant was unable to tolerate any of the study
      medications during the course of the study then their doctor could switch them to another
      regimen.

      During the study, participants was asked to return to the clinic at Weeks 4, 8, 16, 24, 36,
      and 48 and then every 16 weeks until the end of the study. They were also contacted by
      telephone during Week 2 to check on their status. Visits were last about 1 hour. At most
      visits, participants had a physical exam and answered questions about any medications they
      were taken. Additionally, participants completed questionnaires addressing their smoking and
      alcohol habits, had blood drawn, and were asked to give urine samples. At some visits,
      participants had to come to the clinic without having eaten for 8 hours. If the participant
      was female and able to become pregnant, a pregnancy test might be given at any visit if
      pregnancy was suspected.

      Some participants of A5257 were asked to participate in an optional metabolic substudy
      A5260s. This substudy took place at only some study sites and continued last up to 144 weeks,
      including time on A5257. The primary focus of this substudy was to examine carotid artery
      intima-media thickness (CIMT) as it relates to both RTV- and RAL-containing regimens.
      Randomization, stratification, treatment assignments, and study visits were as per A5257.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Probability of First Virologic Failure by Week 96</measure>
    <time_frame>From study entry to week 96</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 96.
Time to virologic failure was defined as the first time from study entry to the first of two consecutive HIV-1 RNA &gt;1000 copies/mL at or after week 16 and before week 24, or &gt;200 copies/mL at or after week 24. Week 16 is defined to occur between 14 (98 days) and 18 weeks (126 days) after study entry, week 24 is defined to occur between 22 (154 days) and 26 (182 days) after study entry, and week 96 is defined to occur between 88 (616 days) and 104 (728 days) after study entry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96</measure>
    <time_frame>From study entry to week 96</time_frame>
    <description>The cumulative incidence of discontinuation for toxicity by week 96 was estimated using competing risks with treatment discontinuation for other reasons considered as a competing event; participants completing the study on the RAL or PI component of their randomized regimen were considered censored at the earliest of the date of last patient contact and off study date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of First Adverse Event by Week 96</measure>
    <time_frame>From study entry to week 96</time_frame>
    <description>The cumulative incidence of first adverse event (with and without total bilirubin and creatine kinase and measured from study entry) by week 96 was estimated using methods for competing risks. Discontinuation of randomized treatment prior to an adverse event was considered a competing event.
The time to the first of any post-entry Grade 2, 3, or 4 sign or symptom, or Grade 3 or 4 laboratory abnormality while on randomization. The protocol required reporting of signs and symptoms and laboratory values as follow: all signs and symptoms grade ≥2 post-entry to week 48, signs and symptoms grade &gt;3 after week 48, and laboratory values grade &gt;3 and all signs, symptoms, and laboratory values that led to a change in treatment, regardless of grade throughout out all post-entry follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96</measure>
    <time_frame>From study entry to week 96</time_frame>
    <description>The Kaplan-Meier estimate of the cumulative probability of TROVR by week 96.
A composite TLOVR endpoint defined in the CDER of the FDA document &quot;Guidance for Industry - Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Consideration for Accelerated and Traditional Approval&quot; (Appendix B, pages 20) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.
If participants never achieved a confirmed HIV-1 RNA≤200 cp/mL (on two consecutive visits) prior to death, permanent discontinuation of randomized treatment, or time of last available HIV-1 RNA evaluation, TLOVR was equal to 0; otherwise, TLOVR was the earliest time of permanent discontinuation of randomized treatment prior to study close-out period, time to confirmed levels &gt;200 cp/mL, or time to death. If TLOVR is immediately preceded by a single missing scheduled visit or multiple consecutive missing scheduled visits, TLOVR is replaced by the first such missing visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Mutations Associated With NRTI Resistance</measure>
    <time_frame>At the virologic failure at any time throughout the study (up to 213 weeks)</time_frame>
    <description>The number of participants with NRTI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance</measure>
    <time_frame>At the virologic failure at any time throughout the study (up to 213 weeks)</time_frame>
    <description>The number of participants with ATV/RTV or DRV/RTV resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Mutations Associated With INI Resistance</measure>
    <time_frame>At the virologic failure at any time throughout the study (up to 213 weeks)</time_frame>
    <description>The number of participants with INI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Count</measure>
    <time_frame>At Weeks 24, 48, 96, and 144</time_frame>
    <description>The absolute levels of CD4+ T-cell counts (cells/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Count Changes From Baseline</measure>
    <time_frame>Study entry to weeks 24, 48, 96, and 144</time_frame>
    <description>Change was calculated as the CD4+ T-cell count at week (24, 48, 96, and 144) minus the baseline CD4+ T-cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death or AIDS Defining Events (CDC Category C)</measure>
    <time_frame>Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable</time_frame>
    <description>The incidence of death or AIDS defining events (CDC category C) was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD)</measure>
    <time_frame>Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable</time_frame>
    <description>The incidence of targeted serious non-AIDS defining events was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Total Cholesterol Level From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Only fasting results are included. Change was calculated as the fasting total cholesterol at week (48, 96, and 144) minus the baseline fasting total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting HDL Cholesterol Level From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Only fasting results are included. Change was calculated as the fasting HDL cholesterol at week (48, 96, and 144) minus the baseline fasting HDL cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglycerides Level From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Only fasting results are included. Change was calculated as the fasting triglycerides at week (48, 96, and 144) minus the baseline fasting triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose Level From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Only fasting results are included. Change was calculated as the fasting plasma glucose at week (48, 96, and 144) minus the baseline fasting plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Framingham 10-year Risk of MI or Coronary Death From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Only risk score estimated with fasting lipid results were included. Change was calculated as the Framingham 10-year risk of MI or coronary death at week (48, 96, and 144) minus the baseline Framingham 10-year risk of MI or coronary death. Framingham 10-year risk of MI or coronary death was calculated using Hear Coronary Heart Disease (10-year risk) found at https://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/hard-10-year-risk.php.
Framingham 10-year risk of MI or coronary death was calculated according to age, laboratory values of total cholesterol and HDL cholesterol, smoking status, systolic blood pressure, and treatment for hypertension. The Framingham 10-year risk of MI or coronary death was calculated as: for males: &lt;0 point (&lt;1 percent risk) up to ≥17 points (≥30 percent risk); whereas for females: &lt;9 points (&lt;1 percent risk) up to ≥25 points (≥30 percent risk). Higher scores indicate high cardiovascular risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Change was calculated as the waist circumference (based on mid-waist circumference) at week (48, 96, and 144) minus the baseline waist circumference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist:Height Ratio From Baseline</measure>
    <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
    <description>Change was calculated as the waist:height ratio at week (48, 96, and 144) minus the baseline waist:height ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Adherence</measure>
    <time_frame>At Weeks 4, 24, 48, 96, and 144</time_frame>
    <description>Self-reported percentage of anti-HIV medications participant had taken during the last month at weeks 4, 24, 48, 96, and 144.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1814</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: ATV/RTV + FTC/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: RAL + FTC/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: DRV/RTV + FTC/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/tenofovir disoproxil fumarate</intervention_name>
    <description>200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).</description>
    <arm_group_label>Arm A: ATV/RTV + FTC/TDF</arm_group_label>
    <arm_group_label>Arm B: RAL + FTC/TDF</arm_group_label>
    <arm_group_label>Arm C: DRV/RTV + FTC/TDF</arm_group_label>
    <other_name>TDF/FTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg taken orally twice daily. An integrase inhibitor (INI).</description>
    <arm_group_label>Arm B: RAL + FTC/TDF</arm_group_label>
    <other_name>RAL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>800 mg taken orally once daily. A protease inhibitor (PI).</description>
    <arm_group_label>Arm C: DRV/RTV + FTC/TDF</arm_group_label>
    <other_name>DRV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100 mg taken orally once daily. A protease inhibitor (PI).</description>
    <arm_group_label>Arm A: ATV/RTV + FTC/TDF</arm_group_label>
    <arm_group_label>Arm C: DRV/RTV + FTC/TDF</arm_group_label>
    <other_name>RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>300 mg taken orally once daily. A protease inhibitor (PI).</description>
    <arm_group_label>Arm A: ATV/RTV + FTC/TDF</arm_group_label>
    <other_name>ATV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  No evidence of any exclusionary mutations defined as any major NRTI or PI
             resistance-associated mutation on any genotype or evidence of significant NRTI or PI
             resistance on any phenotype performed at any time prior to study entry.
             NNRTI-associated resistance mutations are not excluded. More information on this
             criterion can be found in the study protocol.

          -  No prior anti-HIV therapy. More information on this criterion can be found in the
             study protocol.

          -  Viral load is 1000 copies/mL or higher, as measured within 90 days prior to study
             entry

          -  Certain laboratory values obtained within 60 days prior to study entry

          -  Ability to obtain RTV by prescription

          -  Completed cardiovascular risk assessment. More information on this criterion can be
             found in the study protocol.

          -  Must agree to use acceptable forms of contraception while receiving study drugs and
             for 6 weeks after stopping the medications. More information on this criterion is
             available in the protocol.

          -  Negative pregnancy test within 72 hours before initiating antiretroviral medication

          -  Participating in research at any AIDS Clinical Trial Group (ACTG) clinical research
             site or select International Maternal Pediatric Adolescent AIDS Clinical Trials
             (IMPAACT) group sites

          -  Ability and willingness of subject or legal guardian/representative to give written
             informed consent

        Exclusion Criteria:

          -  Use of immunomodulators, HIV vaccine, systemic cytotoxic chemotherapy, or
             investigational therapy within 30 days prior to study entry. Those using stable
             physiologic glucocorticoid doses, a short course of pharmacologic glucocorticoid,
             corticosteroids for acute therapy treating an opportunistic infection, inhaled or
             topical corticosteroids, or granulocyte-colony stimulating factor (G-CSF) or
             granulocyte-macrophage colony-stimulating factor (GM-CSF) will not be excluded.

          -  Known allergy or sensitivity to study drugs or their ingredients. A history of sulfa
             allergy is not excluded.

          -  Any condition that, in the opinion of the investigator, would compromise the
             participant's ability to participate in the study

          -  Serious illness requiring systemic treatment and/or hospitalization until participant
             either completes therapy or is clinically stable on therapy, in the opinion of the
             investigator, for at least 7 days prior to study entry

          -  Requirement for any current medications that are prohibited with any study drugs

          -  Current imprisonment or involuntary incarceration in a medical facility for
             psychiatric or physical illness

          -  Any prior use of entecavir for treatment of hepatitis B for greater than 8 weeks while
             the participant was known to be HIV infected

          -  Presence of decompensated cirrhosis

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L. Lennox, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory HIV/AIDS CTU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Silverstein Currier, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>UCLA AIDS Prevention &amp; Treatment CTU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raphael Landovitz, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>UCLA AIDS Prevention &amp; Treatment CTU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igho Ofotokun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory HIV/AIDS CTU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Public Health CRS</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University CRS (GU CRS)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Childrens Diagnostic &amp; Treatment Cen (5055)</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville (5051)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University New Orleans NICHD CRS (5095)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med. Ctr., ACTG CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State Univ. CRS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp. CRS</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Univ. Hosp. CRS</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School- Adult Clinical Research Ctr. CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hosp. Ctr. CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Prevention &amp; Treatment CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Care CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook NICHD CRS (5040)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Center for Infectious Disease, Wendover Medical Center CRS (3203)</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research &amp; Education Group- Portland CRS (31474)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hosp. ACTG CRS</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude/UTHSC CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth Univ. Medical Ctr. CRS</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials. 2007 Jul-Aug;8(4):221-6. Review.</citation>
    <PMID>17720662</PMID>
  </reference>
  <reference>
    <citation>Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18.</citation>
    <PMID>18641035</PMID>
  </reference>
  <reference>
    <citation>Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.</citation>
    <PMID>17721395</PMID>
  </reference>
  <reference>
    <citation>Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D; CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008 Aug 23;372(9639):646-55. doi: 10.1016/S0140-6736(08)61081-8.</citation>
    <PMID>18722869</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <results_first_submitted>June 23, 2014</results_first_submitted>
  <results_first_submitted_qc>September 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment naive</keyword>
  <keyword>Treatment inexperienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited at AIDS Clinical Trials Units in the United States and Puerto Rico. Recruitment occurred between May 22, 2009 (date first subject was randomized) and June 9, 2011 (date last subject was randomized).</recruitment_details>
      <pre_assignment_details>1814 were randomized 1:1:1 to treatment arms A, B, and C. Results reported for 1809 eligible participants; 5 were subsequently found ineligible and excluded from all analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: ATV/RTV + FTC/TDF</title>
          <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
        </group>
        <group group_id="P2">
          <title>Arm B: RAL + FTC/TDF</title>
          <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
        </group>
        <group group_id="P3">
          <title>Arm C: DRV/RTV + FTC/TDF</title>
          <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="605"/>
                <participants group_id="P2" count="603"/>
                <participants group_id="P3" count="601"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="516"/>
                <participants group_id="P2" count="531"/>
                <participants group_id="P3" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not able to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not willing to adhere to requirements</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdraw consent prior study completion</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe Debilitation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Complete Protocol: No follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat: All eligible participants were included in the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: ATV/RTV + FTC/TDF</title>
          <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
        </group>
        <group group_id="B2">
          <title>Arm B: RAL + FTC/TDF</title>
          <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
        </group>
        <group group_id="B3">
          <title>Arm C: DRV/RTV + FTC/TDF</title>
          <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="605"/>
            <count group_id="B2" value="603"/>
            <count group_id="B3" value="601"/>
            <count group_id="B4" value="1809"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="597"/>
                    <measurement group_id="B2" value="598"/>
                    <measurement group_id="B3" value="595"/>
                    <measurement group_id="B4" value="1790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="11"/>
                    <measurement group_id="B2" value="37" spread="11"/>
                    <measurement group_id="B3" value="38" spread="11"/>
                    <measurement group_id="B4" value="37" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="461"/>
                    <measurement group_id="B2" value="455"/>
                    <measurement group_id="B3" value="458"/>
                    <measurement group_id="B4" value="1374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race/Ethnicity was collected prior to study entry</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="191"/>
                    <measurement group_id="B4" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="251"/>
                    <measurement group_id="B4" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Regardless of Race)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="148"/>
                    <measurement group_id="B4" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian, Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA</title>
          <description>HIV-1 RNA was calculated as the geometric mean of the two most recent HIV-1 RNA (log 10 copies/mL) obtained on or before study entry. In the event that these two values differed by more than 1log10 copy/mL, the outlying value (based on review of all HIV-1 RNA levels available prior to study entry by the study virologist) was excluded and baseline determined by the remaining sample. Note that screening HIV-1 RNA values were not sued in the calculation of baseline HIV-1 RNA levels.</description>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="0.7"/>
                    <measurement group_id="B2" value="4.6" spread="0.7"/>
                    <measurement group_id="B3" value="4.6" spread="0.7"/>
                    <measurement group_id="B4" value="4.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ T-cell count</title>
          <description>CD4+ T-cell counts were calculated as the mean of the two most recent values available on or before study entry.</description>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309" spread="189"/>
                    <measurement group_id="B2" value="306" spread="199"/>
                    <measurement group_id="B3" value="310" spread="189"/>
                    <measurement group_id="B4" value="308" spread="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Probability of First Virologic Failure by Week 96</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 96.
Time to virologic failure was defined as the first time from study entry to the first of two consecutive HIV-1 RNA &gt;1000 copies/mL at or after week 16 and before week 24, or &gt;200 copies/mL at or after week 24. Week 16 is defined to occur between 14 (98 days) and 18 weeks (126 days) after study entry, week 24 is defined to occur between 22 (154 days) and 26 (182 days) after study entry, and week 96 is defined to occur between 88 (616 days) and 104 (728 days) after study entry.</description>
        <time_frame>From study entry to week 96</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of First Virologic Failure by Week 96</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of virologic failure by week 96.
Time to virologic failure was defined as the first time from study entry to the first of two consecutive HIV-1 RNA &gt;1000 copies/mL at or after week 16 and before week 24, or &gt;200 copies/mL at or after week 24. Week 16 is defined to occur between 14 (98 days) and 18 weeks (126 days) after study entry, week 24 is defined to occur between 22 (154 days) and 26 (182 days) after study entry, and week 96 is defined to occur between 88 (616 days) and 104 (728 days) after study entry.</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>cumulative probability per 100 persons</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="O2" value="10" lower_limit="7" upper_limit="12"/>
                    <measurement group_id="O3" value="15" lower_limit="12" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the difference (arm A - arm B) in the stratified Kaplan-Meier estimate for the week 96 cumulative probability of virologic failure with 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Confidence interval estimation was stratified by HIV-1 RNA level at screening using Greenwood's variance with the inverse of this variance used for the stratum weights. The pre-specified confidence bounds for equivalence were +/-10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative probability difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the difference (arm C - arm B) in the stratified Kaplan-Meier estimate for the week 96 cumulative probability of virologic failure with 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Confidence interval estimation was stratified by HIV-1 RNA level at screening using Greenwood's variance with the inverse of this variance used for the stratum weights. The pre-specified confidence bounds for equivalence were +/-10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative probability difference</param_type>
            <param_value>5.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the difference (arm A - arm C) in the stratified Kaplan-Meier estimate for the week 96 cumulative probability of virologic failure with 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Confidence interval estimation was stratified by HIV-1 RNA level at screening using Greenwood's variance with the inverse of this variance used for the stratum weights. The pre-specified confidence bounds for equivalence were +/-10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative probability difference</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96</title>
        <description>The cumulative incidence of discontinuation for toxicity by week 96 was estimated using competing risks with treatment discontinuation for other reasons considered as a competing event; participants completing the study on the RAL or PI component of their randomized regimen were considered censored at the earliest of the date of last patient contact and off study date.</description>
        <time_frame>From study entry to week 96</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Discontinuation of the RAL or PI Component of Randomized Treatment for Toxicity by Week 96</title>
          <description>The cumulative incidence of discontinuation for toxicity by week 96 was estimated using competing risks with treatment discontinuation for other reasons considered as a competing event; participants completing the study on the RAL or PI component of their randomized regimen were considered censored at the earliest of the date of last patient contact and off study date.</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>cumulative events per 100 persons</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the methods of Gray. Inference regarding comparisons of the treatment groups (arm A and arm B) with respect to equivalence was made based on the two-sided 97.5% confidence intervals of differences (arm A - arm B) in 96 week probability of tolerability failure with 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Although the study was not specifically powered to be able to detect equivalence, equivalence was declared if the 97.5% confidence interval difference in the cumulative probability of the tolerability endpoint by 96 weeks was entirely contained within +/-10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative incidence difference</param_type>
            <param_value>12.8</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.4</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the methods of Gray. Inference regarding comparisons of the treatment groups (arm C and arm B) with respect to equivalence was made based on the two-sided 97.5% confidence intervals of differences (arm C - arm B) in 96 week probability of tolerability failure with 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Although the study was not specifically powered to be able to detect equivalence, equivalence was declared if the 97.5% confidence interval difference in the cumulative probability of the tolerability endpoint by 96 weeks was entirely contained within +/-10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative incidence difference</param_type>
            <param_value>3.6</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Treatment comparison was made using the methods of Gray. Inference regarding comparisons of the treatment groups (arm A and arm C) with respect to equivalence was made based on the two-sided 97.5% confidence intervals of differences (arm A - arm C) in 96 week probability of tolerability failure with 97.5% confidence interval.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Although the study was not specifically powered to be able to detect equivalence, equivalence was declared if the 97.5% confidence interval difference in the cumulative probability of the tolerability endpoint by 96 weeks was entirely contained within +/-10 percentage points.</non_inferiority_desc>
            <param_type>Cumulative incidence difference</param_type>
            <param_value>9.2</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.5</ci_lower_limit>
            <ci_upper_limit>12.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of First Adverse Event by Week 96</title>
        <description>The cumulative incidence of first adverse event (with and without total bilirubin and creatine kinase and measured from study entry) by week 96 was estimated using methods for competing risks. Discontinuation of randomized treatment prior to an adverse event was considered a competing event.
The time to the first of any post-entry Grade 2, 3, or 4 sign or symptom, or Grade 3 or 4 laboratory abnormality while on randomization. The protocol required reporting of signs and symptoms and laboratory values as follow: all signs and symptoms grade ≥2 post-entry to week 48, signs and symptoms grade &gt;3 after week 48, and laboratory values grade &gt;3 and all signs, symptoms, and laboratory values that led to a change in treatment, regardless of grade throughout out all post-entry follow-up.</description>
        <time_frame>From study entry to week 96</time_frame>
        <population>As treated: Participants who had events occurring while on randomized treatment are included in this analysis: grade 2 events occurring in the after 48 weeks on study are excluded. Participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of First Adverse Event by Week 96</title>
          <description>The cumulative incidence of first adverse event (with and without total bilirubin and creatine kinase and measured from study entry) by week 96 was estimated using methods for competing risks. Discontinuation of randomized treatment prior to an adverse event was considered a competing event.
The time to the first of any post-entry Grade 2, 3, or 4 sign or symptom, or Grade 3 or 4 laboratory abnormality while on randomization. The protocol required reporting of signs and symptoms and laboratory values as follow: all signs and symptoms grade ≥2 post-entry to week 48, signs and symptoms grade &gt;3 after week 48, and laboratory values grade &gt;3 and all signs, symptoms, and laboratory values that led to a change in treatment, regardless of grade throughout out all post-entry follow-up.</description>
          <population>As treated: Participants who had events occurring while on randomized treatment are included in this analysis: grade 2 events occurring in the after 48 weeks on study are excluded. Participants were analyzed per original assigned randomized treatment.</population>
          <units>cumulative events per 100 persons</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="600"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="77" upper_limit="84"/>
                    <measurement group_id="O2" value="59" lower_limit="55" upper_limit="63"/>
                    <measurement group_id="O3" value="65" lower_limit="61" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96</title>
        <description>The Kaplan-Meier estimate of the cumulative probability of TROVR by week 96.
A composite TLOVR endpoint defined in the CDER of the FDA document &quot;Guidance for Industry - Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Consideration for Accelerated and Traditional Approval&quot; (Appendix B, pages 20) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.
If participants never achieved a confirmed HIV-1 RNA≤200 cp/mL (on two consecutive visits) prior to death, permanent discontinuation of randomized treatment, or time of last available HIV-1 RNA evaluation, TLOVR was equal to 0; otherwise, TLOVR was the earliest time of permanent discontinuation of randomized treatment prior to study close-out period, time to confirmed levels &gt;200 cp/mL, or time to death. If TLOVR is immediately preceded by a single missing scheduled visit or multiple consecutive missing scheduled visits, TLOVR is replaced by the first such missing visit.</description>
        <time_frame>From study entry to week 96</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Probability of Time to Loss of Virologic Response (TLOVR) by Week 96</title>
          <description>The Kaplan-Meier estimate of the cumulative probability of TROVR by week 96.
A composite TLOVR endpoint defined in the CDER of the FDA document &quot;Guidance for Industry - Antiretroviral Drugs Using Plasma HIV RNA Measurements - Clinical Consideration for Accelerated and Traditional Approval&quot; (Appendix B, pages 20) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.
If participants never achieved a confirmed HIV-1 RNA≤200 cp/mL (on two consecutive visits) prior to death, permanent discontinuation of randomized treatment, or time of last available HIV-1 RNA evaluation, TLOVR was equal to 0; otherwise, TLOVR was the earliest time of permanent discontinuation of randomized treatment prior to study close-out period, time to confirmed levels &gt;200 cp/mL, or time to death. If TLOVR is immediately preceded by a single missing scheduled visit or multiple consecutive missing scheduled visits, TLOVR is replaced by the first such missing visit.</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>cumulative probability per 100 persons</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="27" upper_limit="35"/>
                    <measurement group_id="O2" value="16" lower_limit="14" upper_limit="19"/>
                    <measurement group_id="O3" value="24" lower_limit="20" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Mutations Associated With NRTI Resistance</title>
        <description>The number of participants with NRTI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
        <time_frame>At the virologic failure at any time throughout the study (up to 213 weeks)</time_frame>
        <population>Participants who met the criteria for virologic failure with successful sequencing at virologic failure</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Mutations Associated With NRTI Resistance</title>
          <description>The number of participants with NRTI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
          <population>Participants who met the criteria for virologic failure with successful sequencing at virologic failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance</title>
        <description>The number of participants with ATV/RTV or DRV/RTV resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
        <time_frame>At the virologic failure at any time throughout the study (up to 213 weeks)</time_frame>
        <population>Participants who met the criteria for virologic failure with successful sequencing at virologic failure</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Mutations Associated With ATV/RTV or DRV/RTV Resistance</title>
          <description>The number of participants with ATV/RTV or DRV/RTV resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
          <population>Participants who met the criteria for virologic failure with successful sequencing at virologic failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Mutations Associated With INI Resistance</title>
        <description>The number of participants with INI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
        <time_frame>At the virologic failure at any time throughout the study (up to 213 weeks)</time_frame>
        <population>Participants who met the criteria for virologic failure restricted to participants in the RAL group and random sample of participants in PI/RTV groups with successful sequencing at virologic failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Mutations Associated With INI Resistance</title>
          <description>The number of participants with INI resistance determined by the Stanford resistance scoring algorithm (Version 6.3). All sequencing was performed regardless of status on randomized treatment at the time of virologic failure; no sequencing was performed on subjects not meeting virologic failure.</description>
          <population>Participants who met the criteria for virologic failure restricted to participants in the RAL group and random sample of participants in PI/RTV groups with successful sequencing at virologic failure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Count</title>
        <description>The absolute levels of CD4+ T-cell counts (cells/mm3)</description>
        <time_frame>At Weeks 24, 48, 96, and 144</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment. Missing data were assumed missing completely at random.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Count</title>
          <description>The absolute levels of CD4+ T-cell counts (cells/mm3)</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment. Missing data were assumed missing completely at random.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24 (nA=582, nB=574, nC=579)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462" lower_limit="443" upper_limit="480"/>
                    <measurement group_id="O2" value="460" lower_limit="440" upper_limit="480"/>
                    <measurement group_id="O3" value="457" lower_limit="438" upper_limit="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48 (nA=564, nB=565, nC=559)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" lower_limit="504" upper_limit="544"/>
                    <measurement group_id="O2" value="526" lower_limit="504" upper_limit="549"/>
                    <measurement group_id="O3" value="509" lower_limit="488" upper_limit="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=523, nB=541, nC=525)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587" lower_limit="565" upper_limit="609"/>
                    <measurement group_id="O2" value="596" lower_limit="573" upper_limit="619"/>
                    <measurement group_id="O3" value="564" lower_limit="541" upper_limit="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=395, nB=418, nC=394)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622" lower_limit="596" upper_limit="648"/>
                    <measurement group_id="O2" value="631" lower_limit="602" upper_limit="660"/>
                    <measurement group_id="O3" value="596" lower_limit="571" upper_limit="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Count Changes From Baseline</title>
        <description>Change was calculated as the CD4+ T-cell count at week (24, 48, 96, and 144) minus the baseline CD4+ T-cell count</description>
        <time_frame>Study entry to weeks 24, 48, 96, and 144</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment. Missing data were assumed missing completely at random.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Count Changes From Baseline</title>
          <description>Change was calculated as the CD4+ T-cell count at week (24, 48, 96, and 144) minus the baseline CD4+ T-cell count</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment. Missing data were assumed missing completely at random.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24 (nA=582, nB=574, nC=579)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" lower_limit="147" upper_limit="167"/>
                    <measurement group_id="O2" value="153" lower_limit="142" upper_limit="163"/>
                    <measurement group_id="O3" value="147" lower_limit="136" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48 (nA=564, nB=565, nC=559)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="206" upper_limit="231"/>
                    <measurement group_id="O2" value="218" lower_limit="205" upper_limit="232"/>
                    <measurement group_id="O3" value="201" lower_limit="187" upper_limit="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=523, nB=541, nC=525)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284" lower_limit="269" upper_limit="300"/>
                    <measurement group_id="O2" value="288" lower_limit="272" upper_limit="304"/>
                    <measurement group_id="O3" value="256" lower_limit="240" upper_limit="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=395, nB=418, nC=394)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324" lower_limit="305" upper_limit="343"/>
                    <measurement group_id="O2" value="325" lower_limit="304" upper_limit="345"/>
                    <measurement group_id="O3" value="288" lower_limit="269" upper_limit="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Death or AIDS Defining Events (CDC Category C)</title>
        <description>The incidence of death or AIDS defining events (CDC category C) was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.</description>
        <time_frame>Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Death or AIDS Defining Events (CDC Category C)</title>
          <description>The incidence of death or AIDS defining events (CDC category C) was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" lower_limit="1.05" upper_limit="2.28"/>
                    <measurement group_id="O2" value="1.64" lower_limit="1.12" upper_limit="2.40"/>
                    <measurement group_id="O3" value="2.14" lower_limit="1.43" upper_limit="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD)</title>
        <description>The incidence of targeted serious non-AIDS defining events was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.</description>
        <time_frame>Study entry to off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable</time_frame>
        <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Targeted Serious Non-AIDS Defining Events (Renal Failure, Liver Disease, Serious Metabolic Disorder, and CVD)</title>
          <description>The incidence of targeted serious non-AIDS defining events was estimated as number of incident events over total person years of follow-up. Multiple new events for a single subject were counted toward events totals in estimation of event incidence; generalized estimating equations were used to estimation of robust standard errors for the incidence.</description>
          <population>Intention to treat: All eligible participants were included in the analysis: participants were analyzed per original assigned randomized treatment.</population>
          <units>events per 100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" lower_limit="1.76" upper_limit="3.23"/>
                    <measurement group_id="O2" value="2.24" lower_limit="1.51" upper_limit="3.32"/>
                    <measurement group_id="O3" value="2.69" lower_limit="1.89" upper_limit="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Total Cholesterol Level From Baseline</title>
        <description>Only fasting results are included. Change was calculated as the fasting total cholesterol at week (48, 96, and 144) minus the baseline fasting total cholesterol.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Total Cholesterol Level From Baseline</title>
          <description>Only fasting results are included. Change was calculated as the fasting total cholesterol at week (48, 96, and 144) minus the baseline fasting total cholesterol.</description>
          <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=521, nB=542, nC=507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="O2" value="1" lower_limit="-2" upper_limit="3"/>
                    <measurement group_id="O3" value="15" lower_limit="12" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=490, nB=505, nC=490)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="13" upper_limit="19"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O3" value="14" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=364, nB=397, nC=363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="15" upper_limit="25"/>
                    <measurement group_id="O2" value="6" lower_limit="2" upper_limit="9"/>
                    <measurement group_id="O3" value="19" lower_limit="16" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting HDL Cholesterol Level From Baseline</title>
        <description>Only fasting results are included. Change was calculated as the fasting HDL cholesterol at week (48, 96, and 144) minus the baseline fasting HDL cholesterol.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting HDL Cholesterol Level From Baseline</title>
          <description>Only fasting results are included. Change was calculated as the fasting HDL cholesterol at week (48, 96, and 144) minus the baseline fasting HDL cholesterol.</description>
          <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=522, nB=542, nC=506)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=490, nB=505, nC=488)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=364, nB=397, nC=363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="7" upper_limit="9"/>
                    <measurement group_id="O2" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O3" value="7" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Triglycerides Level From Baseline</title>
        <description>Only fasting results are included. Change was calculated as the fasting triglycerides at week (48, 96, and 144) minus the baseline fasting triglycerides.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Triglycerides Level From Baseline</title>
          <description>Only fasting results are included. Change was calculated as the fasting triglycerides at week (48, 96, and 144) minus the baseline fasting triglycerides.</description>
          <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=522, nB=542, nC=507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O2" value="-9" lower_limit="-16" upper_limit="-3"/>
                    <measurement group_id="O3" value="16" lower_limit="8" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=490, nB=505, nC=490)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="12" upper_limit="27"/>
                    <measurement group_id="O2" value="-9" lower_limit="-16" upper_limit="-1"/>
                    <measurement group_id="O3" value="16" lower_limit="7" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=364, nB=397, nC=363)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O2" value="-4" lower_limit="-13" upper_limit="4"/>
                    <measurement group_id="O3" value="20" lower_limit="10" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose Level From Baseline</title>
        <description>Only fasting results are included. Change was calculated as the fasting plasma glucose at week (48, 96, and 144) minus the baseline fasting plasma glucose.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose Level From Baseline</title>
          <description>Only fasting results are included. Change was calculated as the fasting plasma glucose at week (48, 96, and 144) minus the baseline fasting plasma glucose.</description>
          <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=517, nB=535, nC=506)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.7" upper_limit="3.8"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-0.3" upper_limit="2.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.8" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=489, nB=499, nC=481)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.4" upper_limit="4.6"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-0.6" upper_limit="2.5"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.5" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=353, nB=392, nC=358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-0.8" upper_limit="5.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-1.6" upper_limit="3.4"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.1" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Framingham 10-year Risk of MI or Coronary Death From Baseline</title>
        <description>Only risk score estimated with fasting lipid results were included. Change was calculated as the Framingham 10-year risk of MI or coronary death at week (48, 96, and 144) minus the baseline Framingham 10-year risk of MI or coronary death. Framingham 10-year risk of MI or coronary death was calculated using Hear Coronary Heart Disease (10-year risk) found at https://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/hard-10-year-risk.php.
Framingham 10-year risk of MI or coronary death was calculated according to age, laboratory values of total cholesterol and HDL cholesterol, smoking status, systolic blood pressure, and treatment for hypertension. The Framingham 10-year risk of MI or coronary death was calculated as: for males: &lt;0 point (&lt;1 percent risk) up to ≥17 points (≥30 percent risk); whereas for females: &lt;9 points (&lt;1 percent risk) up to ≥25 points (≥30 percent risk). Higher scores indicate high cardiovascular risk.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Framingham 10-year Risk of MI or Coronary Death From Baseline</title>
          <description>Only risk score estimated with fasting lipid results were included. Change was calculated as the Framingham 10-year risk of MI or coronary death at week (48, 96, and 144) minus the baseline Framingham 10-year risk of MI or coronary death. Framingham 10-year risk of MI or coronary death was calculated using Hear Coronary Heart Disease (10-year risk) found at https://www.framinghamheartstudy.org/risk-functions/coronary-heart-disease/hard-10-year-risk.php.
Framingham 10-year risk of MI or coronary death was calculated according to age, laboratory values of total cholesterol and HDL cholesterol, smoking status, systolic blood pressure, and treatment for hypertension. The Framingham 10-year risk of MI or coronary death was calculated as: for males: &lt;0 point (&lt;1 percent risk) up to ≥17 points (≥30 percent risk); whereas for females: &lt;9 points (&lt;1 percent risk) up to ≥25 points (≥30 percent risk). Higher scores indicate high cardiovascular risk.</description>
          <population>Intention to treat: All participants with fasting lipids data were included, complete-case approach.</population>
          <units>percent risk</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=509, nB=537, nC=492)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.2" upper_limit="0.1"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=479, nB=493, nC=470)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.2" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=347, nB=383, nC=349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.3" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.2" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.6" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference From Baseline</title>
        <description>Change was calculated as the waist circumference (based on mid-waist circumference) at week (48, 96, and 144) minus the baseline waist circumference.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with waist circumference data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference From Baseline</title>
          <description>Change was calculated as the waist circumference (based on mid-waist circumference) at week (48, 96, and 144) minus the baseline waist circumference.</description>
          <population>Intention to treat: All participants with waist circumference data were included, complete-case approach.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=555, nB=551, nC=547)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.7" upper_limit="2.9"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.5" upper_limit="3.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.5" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=512, nB=526, nC=517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.3" upper_limit="4.7"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.2" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=425, nB=419, nC=409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.9" upper_limit="4.4"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.2" upper_limit="4.8"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.7" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist:Height Ratio From Baseline</title>
        <description>Change was calculated as the waist:height ratio at week (48, 96, and 144) minus the baseline waist:height ratio.</description>
        <time_frame>Study entry to weeks 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with waist circumference data were included, complete-case approach.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist:Height Ratio From Baseline</title>
          <description>Change was calculated as the waist:height ratio at week (48, 96, and 144) minus the baseline waist:height ratio.</description>
          <population>Intention to treat: All participants with waist circumference data were included, complete-case approach.</population>
          <units>cm:cm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 (nA=555, nB=551, nC=547)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O3" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=512, nB=526, nC=517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0.02" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O3" value="0.02" lower_limit="0.01" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=425, nB=419, nC=409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O3" value="0.02" lower_limit="0.02" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Adherence</title>
        <description>Self-reported percentage of anti-HIV medications participant had taken during the last month at weeks 4, 24, 48, 96, and 144.</description>
        <time_frame>At Weeks 4, 24, 48, 96, and 144</time_frame>
        <population>Intention to treat: All participants with fasting self-reported adherence data were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: ATV/RTV + FTC/TDF</title>
            <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
          </group>
          <group group_id="O2">
            <title>Arm B: RAL + FTC/TDF</title>
            <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
          </group>
          <group group_id="O3">
            <title>Arm C: DRV/RTV + FTC/TDF</title>
            <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Adherence</title>
          <description>Self-reported percentage of anti-HIV medications participant had taken during the last month at weeks 4, 24, 48, 96, and 144.</description>
          <population>Intention to treat: All participants with fasting self-reported adherence data were included.</population>
          <units>percentage of prescribed medication</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="603"/>
                <count group_id="O3" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 (nA=584, nB=590, nC=583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="98" upper_limit="99"/>
                    <measurement group_id="O2" value="97" lower_limit="97" upper_limit="98"/>
                    <measurement group_id="O3" value="98" lower_limit="98" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24 (nA=570, nB=568, nC=562)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="98"/>
                    <measurement group_id="O2" value="97" lower_limit="96" upper_limit="97"/>
                    <measurement group_id="O3" value="96" lower_limit="95" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48 (nA=555, nB=547, nC=536)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="95" upper_limit="97"/>
                    <measurement group_id="O2" value="97" lower_limit="96" upper_limit="97"/>
                    <measurement group_id="O3" value="96" lower_limit="95" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 (nA=508, nB=525, nC=507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="97"/>
                    <measurement group_id="O2" value="96" lower_limit="95" upper_limit="97"/>
                    <measurement group_id="O3" value="96" lower_limit="95" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 144 (nA=361, nB=376, nC=350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="98"/>
                    <measurement group_id="O2" value="97" lower_limit="96" upper_limit="97"/>
                    <measurement group_id="O3" value="98" lower_limit="97" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From treatment dispensation until off-study at any time throughout the study (up to 213 weeks), participant follow-up time was variable</time_frame>
      <desc>The DAIDS Adverse Event (AE) Grading Table, Version 1.0, December 2004 (Clarification, August 2009) was used for grading of AEs. Expedited adverse event reporting followed “Manual for Expedited Reporting of Adverse Events to DAIDS” (DAIDS EAE Manual), dated May 6, 2004.
MedDRA version 17.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: ATV/RTV + FTC/TDF</title>
          <description>Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Ritonavir: A protease inhibitor (PI) Atazanavir: A protease inhibitor (PI)</description>
        </group>
        <group group_id="E2">
          <title>Arm B: RAL + FTC/TDF</title>
          <description>FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Raltegravir: An integrase inhibitor (INI)</description>
        </group>
        <group group_id="E3">
          <title>Arm C: DRV/RTV + FTC/TDF</title>
          <description>FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
Emtricitabine/tenofovir disoproxil fumarate: A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs) Darunavir: A protease inhibitor (PI) Ritonavir: A protease inhibitor (PI)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Methaemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Necrotising granulomatous lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pericarditis constrictive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Necrotising retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Disseminated cytomegaloviral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Eye infection syphilitic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hepatitis syphilitic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Osteomyelitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Proctitis herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Viral myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Laryngeal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Intervertebral disc space narrowing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Anal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Mucoepidermoid carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Ocular neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Mediastinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cyst removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="565" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="516" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="532" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="318" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="227" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="183" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="603"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social &amp; Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

